A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: sequence (30), series (135), string (9), succession (39)

Myeloma VCD (IV35) bortezomib (IV) cyclophosphamide dexamethasone 35 day

Description
Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-35) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen Multiple Myeloma – VCD (IV-35)-Bortezomib (IV
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-IV35-bortezomib-IV-cyclophosphamide-dexamethasone-35-day.pdf

Appendix B - VZIG risk assessment and prescription form

Description
Varicella zoster Immunoglobulin for post-exposure prophylaxis (PEP)Please note that UHS Pharmacy will issue VZIG only
Url
/Media/UHS-website-2019/Docs/Post-Exposure-Prophylaxis-Policy/AppendixB-VZIGRiskAssessmentandPrescriptionForm.pdf

Papers Trust Board - 15 July 2025

Description
Agenda Trust Board – Open Session Date 15/07/2025 Time 9:00 - 13:00 Location Conference Room, Heartbeat Education Centre Chair
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-15-July-2025.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description
Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Indication • Isatuximab is indicated where; - the patient has
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Annual-report-and-quality-account-2019-20

Description
ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

Annual report 2021-2022

Description
2021/22 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2021/22 Presented to Parliament
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-2021-2022.pdf

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description
Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexamethasone Indication • Daratumumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

MyelomaRCDCyclophosphamideDexamethasoneLenalidomidel(RCD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA RCD-CYCLOPHOSPHAMIDE-DEXAMETHASONE-LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you have
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaRCDCyclophosphamideDexamethasoneLenalidomidelRCDVer1.pdf

MyelomaCTDa28CyclophosphamideDexamethasoneThalidomideAttenuated(CTDa)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA CTDa (28)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (ATTENUATED) (CTDa-28) There are multiple versions of this protocol in use
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTDa28CyclophosphamideDexamethasoneThalidomideAttenuatedCTDaVer1.pdf
41 to 50 of 85
Previous … 3 4 5 6 7 … Next